Cytosorbents Corporation (CTSO) Earning Somewhat Favorable News Coverage, Report Shows
Media coverage about Cytosorbents Corporation (NASDAQ:CTSO) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytosorbents Corporation earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.5607698266382 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Shares of Cytosorbents Corporation (NASDAQ CTSO) traded down 0.8214% during trading on Friday, reaching $5.1077. 6,113 shares of the company traded hands. Cytosorbents Corporation has a 1-year low of $3.30 and a 1-year high of $6.90. The stock’s 50 day moving average is $4.94 and its 200 day moving average is $4.78. The company’s market capitalization is $143.69 million.
Cytosorbents Corporation (NASDAQ:CTSO) last released its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The company had revenue of $3.57 million for the quarter, compared to analyst estimates of $3.29 million. Cytosorbents Corporation had a negative return on equity of 529.95% and a negative net margin of 80.56%. On average, analysts forecast that Cytosorbents Corporation will post ($0.27) EPS for the current year.
Several research firms have recently issued reports on CTSO. B. Riley restated a “buy” rating and set a $11.25 price objective on shares of Cytosorbents Corporation in a report on Saturday, August 12th. HC Wainwright set a $13.00 price objective on shares of Cytosorbents Corporation and gave the company a “buy” rating in a report on Tuesday, August 8th. Maxim Group upped their price objective on shares of Cytosorbents Corporation from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 8th. Aegis restated a “buy” rating and set a $9.00 price objective on shares of Cytosorbents Corporation in a report on Tuesday, July 25th. Finally, Cowen and Company began coverage on shares of Cytosorbents Corporation in a report on Wednesday, June 7th. They set an “outperform” rating and a $7.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $12.71.
In other news, insider Phillip P. Chan purchased 6,300 shares of the business’s stock in a transaction on Monday, June 5th. The shares were bought at an average price of $4.00 per share, with a total value of $25,200.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders have acquired 16,500 shares of company stock worth $66,280. 5.60% of the stock is currently owned by corporate insiders.
About Cytosorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corporation and related companies with MarketBeat.com's FREE daily email newsletter.